In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Novo Nordisk ADR (NYSE: NVO) closed at $138.60 down -3.06% from its previous closing price of $142.98. In other words, the price has decreased by -$3.06 from its previous closing price. On the day, 7.46 million shares were traded. NVO stock price reached its highest trading level at $141.52 during the session, while it also had its lowest trading level at $136.01.
Ratios:
For a deeper understanding of Novo Nordisk ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 343.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 49.82. For the most recent quarter (mrq), Quick Ratio is recorded 0.50 and its Current Ratio is at 0.70. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on May 30, 2024, initiated with a Buy rating and assigned the stock a target price of $156.
On April 12, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $163.
On January 23, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $120.Morgan Stanley initiated its Overweight rating on January 23, 2024, with a $120 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 620859949056 and an Enterprise Value of 636929638400. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 47.86, and their Forward P/E ratio for the next fiscal year is 33.16. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 17.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.03 while its Price-to-Book (P/B) ratio in mrq is 43.15. Its current Enterprise Value per Revenue stands at 2.608 whereas that against EBITDA is 5.405.
Stock Price History:
Over the past 52 weeks, NVO has reached a high of $148.15, while it has fallen to a 52-week low of $75.56. The 50-Day Moving Average of the stock is 2.49%, while the 200-Day Moving Average is calculated to be 19.77%.
Shares Statistics:
For the past three months, NVO has traded an average of 3.73M shares per day and 4279320 over the past ten days. A total of 3.38B shares are outstanding, with a floating share count of 3.34B. Insiders hold about 0.02% of the company’s shares, while institutions hold 9.74% stake in the company. Shares short for NVO as of 1718323200 were 4480354 with a Short Ratio of 1.17, compared to 1715731200 on 3706203.
Dividends & Splits
The stock’s 5-year Average Dividend Yield is 1.55.
